{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:23:27Z","timestamp":1783495407991,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T00:00:00Z","timestamp":1518480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shire Development LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00787-018-1113-4","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T01:07:03Z","timestamp":1518484023000},"page":"1283-1294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD"],"prefix":"10.1007","volume":"27","author":[{"given":"Michael","family":"Huss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Dirks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Newcorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Antoni","family":"Ramos-Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,13]]},"reference":[{"issue":"6","key":"1113_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","volume":"164","author":"G Polanczyk","year":"2007","unstructured":"Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164(6):942\u2013948. \n                    https:\/\/doi.org\/10.1176\/ajp.2007.164.6.942","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1113_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/jcpp.12381","volume":"56","author":"GV Polanczyk","year":"2015","unstructured":"Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA (2015) Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 56(3):345\u2013365. \n                    https:\/\/doi.org\/10.1111\/jcpp.12381","journal-title":"J Child Psychol Psychiatry"},{"issue":"2","key":"1113_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1037\/0021-843X.111.2.279","volume":"111","author":"RA Barkley","year":"2002","unstructured":"Barkley RA, Fischer M, Smallish L, Fletcher K (2002) The persistence of attention-deficit\/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 111(2):279\u2013289. \n                    https:\/\/doi.org\/10.1037\/0021-843X.111.2.279","journal-title":"J Abnorm Psychol"},{"issue":"2","key":"1113_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1017\/S003329170500471X","volume":"36","author":"SV Faraone","year":"2006","unstructured":"Faraone SV, Biederman J, Mick E (2006) The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 36(2):159\u2013165. \n                    https:\/\/doi.org\/10.1017\/S003329170500471X","journal-title":"Psychol Med"},{"issue":"2","key":"1113_CR5","doi-asserted-by":"publisher","first-page":"e0116407","DOI":"10.1371\/journal.pone.0116407","volume":"10","author":"LE Arnold","year":"2015","unstructured":"Arnold LE, Hodgkins P, Caci H, Kahle J, Young S (2015) Effect of treatment modality on long-term outcomes in attention-deficit\/hyperactivity disorder: a systematic review. PLoS One 10(2):e0116407. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0116407","journal-title":"PLoS One"},{"key":"1113_CR6","volume-title":"The NICE guideline on diagnosis and management of ADHD in children, young people and adults","author":"The British Psychological Society and The Royal College of Psychiatrists","year":"2016","unstructured":"The British Psychological Society and The Royal College of Psychiatrists (2016) The NICE guideline on diagnosis and management of ADHD in children, young people and adults. National Institute for Health and Care Excellence, London"},{"issue":"5","key":"1113_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1542\/peds.2011-2654","volume":"128","author":"M Wolraich","year":"2011","unstructured":"Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S, Subcommittee on attention-deficit\/hyperactivity disorder, steering committee on quality improvement and management (2011) ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics 128(5):1007\u20131022. \n                    https:\/\/doi.org\/10.1542\/peds.2011-2654","journal-title":"Pediatrics"},{"issue":"6","key":"1113_CR8","doi-asserted-by":"publisher","first-page":"e010508","DOI":"10.1136\/bmjopen-2015-010508","volume":"6","author":"R Beau-Lejdstrom","year":"2016","unstructured":"Beau-Lejdstrom R, Douglas I, Evans SJ, Smeeth L (2016) Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open 6(6):e010508. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2015-010508","journal-title":"BMJ Open"},{"issue":"3","key":"1113_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3810\/pgm.2012.05.2557","volume":"124","author":"J Lachaine","year":"2012","unstructured":"Lachaine J, Beauchemin C, Sasane R, Hodgkins PS (2012) Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. Postgrad Med 124(3):139\u2013148. \n                    https:\/\/doi.org\/10.3810\/pgm.2012.05.2557","journal-title":"Postgrad Med"},{"issue":"4","key":"1113_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/01.chi.0000199026.91699.20","volume":"45","author":"A Charach","year":"2006","unstructured":"Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R (2006) Stimulant treatment over 5\u00a0years: effects on growth. J Am Acad Child Adolesc Psychiatry 45(4):415\u2013421. \n                    https:\/\/doi.org\/10.1097\/01.chi.0000199026.91699.20","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"1113_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/chi.0b013e3180686d7e","volume":"46","author":"JM Swanson","year":"2007","unstructured":"Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein JN, Pelham WE, Abikoff HB, Newcorn JH, Molina BS, Hinshaw SP, Wells KC, Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli A, Davies M, March JS, Conners CK, Caron M, Volkow ND (2007) Effects of stimulant medication on growth rates across 3\u00a0years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 46(8):1015\u20131027. \n                    https:\/\/doi.org\/10.1097\/chi.0b013e3180686d7e","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1113_CR12","unstructured":"European Medicines Agency. Intuniv: EPAR\u2014product information (2015). \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003759\/WC500195130.pdf\n                    \n                  . Accessed 21 December 2016"},{"issue":"14","key":"1113_CR13","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1017\/s003329171500104x","volume":"45","author":"A Vannucci","year":"2015","unstructured":"Vannucci A, Nelson EE, Bongiorno DM, Pine DS, Yanovski JA, Tanofsky-Kraff M (2015) Behavioral and neurodevelopmental precursors to binge-type eating disorders: support for the role of negative valence systems. Psychol Med 45(14):2921\u20132936. \n                    https:\/\/doi.org\/10.1017\/s003329171500104x","journal-title":"Psychol Med"},{"key":"1113_CR14","unstructured":"Intuniv\u00ae (guanfacine) capsules US prescribing information (revised March 2016). \n                    http:\/\/pi.shirecontent.com\/PI\/PDFs\/Intuniv_USA_ENG.pdf\n                    \n                  . Accessed 14 October 2016"},{"issue":"1","key":"1113_CR15","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1542\/peds.2006-3695","volume":"121","author":"J Biederman","year":"2008","unstructured":"Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N (2008) A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder. Pediatrics 121(1):e73\u2013e84. \n                    https:\/\/doi.org\/10.1542\/peds.2006-3695","journal-title":"Pediatrics"},{"issue":"2","key":"1113_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/chi.0b013e318191769e","volume":"48","author":"FR Sallee","year":"2009","unstructured":"Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, SPD503 Study Group (2009) Guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48(2):155\u2013165. \n                    https:\/\/doi.org\/10.1097\/chi.0b013e318191769e","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"1113_CR17","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.euroneuro.2014.09.014","volume":"24","author":"A Hervas","year":"2014","unstructured":"Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B (2014) Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol 24(12):1861\u20131872. \n                    https:\/\/doi.org\/10.1016\/j.euroneuro.2014.09.014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"1113_CR18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jaac.2015.08.016","volume":"54","author":"TE Wilens","year":"2015","unstructured":"Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ (2015) A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 54(11):916\u2013925. \n                    https:\/\/doi.org\/10.1016\/j.jaac.2015.08.016\n                    \n                   (e912)","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"1113_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/jcpp.12492","volume":"57","author":"JH Newcorn","year":"2016","unstructured":"Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M, Ramos-Quiroga JA, van Stralen J, Dutray B, Sreckovic S, Bloomfield R, Robertson B (2016) Extended-release guanfacine hydrochloride in 6\u201317-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry 57(6):717\u2013728. \n                    https:\/\/doi.org\/10.1111\/jcpp.12492","journal-title":"J Child Psychol Psychiatry"},{"issue":"12","key":"1113_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1017\/S1092852900017107","volume":"13","author":"J Biederman","year":"2008","unstructured":"Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A (2008) Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 13(12):1047\u20131055. \n                    https:\/\/doi.org\/10.1017\/S1092852900017107","journal-title":"CNS Spectr"},{"issue":"3","key":"1113_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/cap.2008.0080","volume":"19","author":"FR Sallee","year":"2009","unstructured":"Sallee FR, Lyne A, Wigal T, McGough JJ (2009) Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol 19(3):215\u2013226. \n                    https:\/\/doi.org\/10.1089\/cap.2008.0080","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1113_CR22","unstructured":"European Medicines Agency. Summary of the risk management plan (RMP) for Intuniv (guanfacine) (2015). \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Risk-management-plan_summary\/human\/003759\/WC500190181.pdf\n                    \n                  . Accessed 21 December 2016"},{"issue":"246","key":"1113_CR23","first-page":"1","volume":"11","author":"RJ Kuczmarski","year":"2002","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL (2002) 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11(246):1\u2013190","journal-title":"Vital Health Stat"},{"key":"1113_CR24","volume-title":"ADHD Rating Scale-IV: checklists, norms, and clinical interpretation","author":"GJ DuPaul","year":"1998","unstructured":"DuPaul GJ (1998) ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. Guilford Press, New York"},{"key":"1113_CR25","first-page":"218","volume-title":"The ECDEU assessment manual for psychopharmacology-revised volume","author":"W Guy","year":"1976","unstructured":"Guy W (1976) Clinical global impressions. The ECDEU assessment manual for psychopharmacology-revised volume, 338th edn. US Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, pp 218\u2013222","edition":"338"}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00787-018-1113-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-018-1113-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-018-1113-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T19:27:36Z","timestamp":1549999656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00787-018-1113-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,13]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1113"],"URL":"https:\/\/doi.org\/10.1007\/s00787-018-1113-4","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,13]]},"assertion":[{"value":"19 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J\u00a0Gu and B Robertson are employees of Shire and own stock or stock options. B Dirks is a former employee of Shire. The following authors have received compensation for serving as consultants or speakers for, or they or the institutions they work for have received research support or royalties from, the companies or organizations indicated: M Huss (Actelion, Eli Lilly, Engelhard Arzneimittel, Janssen-Cilag, Medice, Novartis, Shire, and Steiner Arzneimittel); J Newcorn (Akili Interactive, Alcobra, Enzymotec, Ironshore, Lundbeck, Medice, National Football League, Neos Therapeutics, NLS, Pearson, Shire, Sunovion, and Supernus); and JA Ramos-Quiroga (Ferrer, Eli Lilly, Janssen-Cilag, Novartis, Lundbeck, Shire, Rovi, and Laboratorios Rubi\u00f3). Study funded by Shire Development LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}